Clinical Genome Resource

Clinical Genome Resource
Name	Clinical Genome Resource
Abbreviation	ClinGen
Formation	2013
Purpose	Curate clinical relevance of genes and variants for precision medicine
Headquarters	United States
Leader title	Executive Director
Leader name	Not specified
Website	Not included

Clinical Genome Resource The Clinical Genome Resource is a large-scale collaboration that curates the clinical relevance of genes and variants to support genomic medicine, precision oncology, and rare disease diagnosis. It connects stakeholders across academic centers, government agencies, industry partners, and patient advocacy groups to standardize interpretation, harmonize curation, and accelerate implementation of genomic information in clinical settings.

Overview

ClinGen operates as a consortium that integrates expertise from National Institutes of Health, Broad Institute, Johns Hopkins University, University of California, San Francisco, Massachusetts General Hospital, Harvard Medical School, Stanford University, Mayo Clinic, Clinical Laboratory Improvement Amendments, Food and Drug Administration, and diverse international partners such as European Molecular Biology Laboratory and Wellcome Trust Sanger Institute. The resource produces consensus-driven gene-disease validity classifications, variant pathogenicity assertions, dosage sensitivity maps, and evidence frameworks used by laboratories, clinics, and regulatory bodies including American College of Medical Genetics and Genomics, Association for Molecular Pathology, Global Alliance for Genomics and Health, and payers such as Centers for Medicare and Medicaid Services. ClinGen’s activities intersect with initiatives like All of Us Research Program, 100,000 Genomes Project, ENCODE Project, and disease-specific networks including Undiagnosed Diseases Network and Orphanet.

History and Development

ClinGen was launched with funding from the National Human Genome Research Institute to address reproducibility and consistency problems highlighted by variants reported in databases such as ClinVar and by findings from projects like the Human Genome Project and 1000 Genomes Project. Early milestones included development of evidence frameworks inspired by consensus efforts from American College of Medical Genetics and Genomics, guideline harmonization with Association for Molecular Pathology, and community-driven pilot curation programs coordinated with institutions such as Yale University, University of Washington, and Children’s Hospital of Philadelphia. Over time ClinGen expanded through collaboration with international consortia including Genomics England, European Society of Human Genetics, and standards groups like ISO committees and HL7 International working groups.

Organizational Structure and Governance

The consortium is governed through steering committees, expert panels, and working groups that include representatives from academic centers like University of Oxford, King’s College London, University of Cambridge, clinical laboratories such as Invitae, Ambry Genetics, and regulatory and funding organizations including NIH institutes and philanthropic funders like Wellcome Trust and Gordon and Betty Moore Foundation. Operational structure comprises variant curation expert panels, gene curation chairs, informatics teams connected to resources like ClinVar, dbGaP, and the NCBI, and liaison roles with standards bodies such as American Medical Informatics Association and ISO. Governance balances academic leadership with advisory input from patient advocacy organizations including Genetic Alliance and disease-specific groups like Cystic Fibrosis Foundation and Muscular Dystrophy Association.

Key Projects and Tools

Major outputs include the Gene Curation framework, Variant Curation Interface, and Dosage Sensitivity Map integrated with databases such as ClinVar, dbSNP, gnomAD, and platforms from European Genome-phenome Archive. Tools and registries are interoperable with informatics standards from HGVS, LOINC, SNOMED CT, and Human Phenotype Ontology to support pipelines used by centers like Mayo Clinic Laboratories, ARUP Laboratories, and biomedical informatics units at Vanderbilt University Medical Center. Collaborations produce curated lists for actionable genes comparable to efforts by ACMG and pilot projects aligned with diagnostics programs at Children’s Hospital of Philadelphia, Boston Children’s Hospital, and international partners engaged with Genomics England.

Clinical and Research Applications

ClinGen resources are used in diagnostic laboratories, clinical decision support systems, clinical trials, newborn screening programs, and translational research at institutions such as Dana-Farber Cancer Institute, MD Anderson Cancer Center, and academic hospitals participating in ClinicalTrials.gov studies. Applications include variant interpretation in oncology panels, cardiomyopathy gene curation for hereditary heart disease centers like Cleveland Clinic, neurogenetic diagnoses in centers such as Boston Children’s Hospital, and integration into electronic health records at systems like Epic Systems Corporation. ClinGen outputs inform guideline development by organizations like ACMG, reimbursement decisions by Centers for Medicare and Medicaid Services, and regulatory reviews by the Food and Drug Administration.

Data Standards, Methods, and Curation

Curation methods follow evidence-based frameworks harmonized with ACMG/AMP guidelines and interoperable data models aligned with schemas from GA4GH and metadata standards such as HL7 FHIR. The consortium uses standardized nomenclature from HGVS and ontologies including Human Phenotype Ontology and Gene Ontology for semantic integration with repositories like dbGaP and European Genome-phenome Archive. Quality control and provenance mechanisms draw on practices from NIST and align with laboratory accreditation standards from College of American Pathologists and regulatory requirements under Clinical Laboratory Improvement Amendments.

Ethical, Legal, and Social Implications

ClinGen engages with ethical, legal, and social issues through partnerships with bioethics centers at Harvard Medical School, Georgetown University, and policy groups including National Academy of Medicine and Presidential Commission for the Study of Bioethical Issues. Topics addressed include informed consent models used in All of Us Research Program and 100,000 Genomes Project, data sharing policies consistent with GDPR and HIPAA, equity in genomic medicine emphasized by initiatives like Global Alliance for Genomics and Health, and patient engagement exemplified by collaborations with Genetic Alliance and disease advocacy organizations. The consortium informs policy discussions at venues such as World Health Organization and regulatory consultations with the Food and Drug Administration.

Category:Genomics